Patent: 10,519,208
✉ Email this page to a colleague
Summary for Patent: 10,519,208
| Title: | CD40L single-chain fusion polypeptides and encoding nucleic acids |
| Abstract: | The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications. |
| Inventor(s): | Oliver Hill, Christian Gieffers, Meinolf Thiemann |
| Assignee: | Apogenix AG |
| Application Number: | US16/289,361 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,519,208
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.s.a., Inc. | VONVENDI | von willebrand factor (recombinant) | For Injection | 125577 | 8-Dec-15 | 10,519,208 | 2039-02-28 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,519,208
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2731388 | ⤷ Start Trial |
| Canada | 2910512 | ⤷ Start Trial |
| Canada | 3092223 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
